Jiangsu Nuohe Bituo New Drug Research and Development Co., Ltd

Primary objective: To evaluate the clinical effectiveness of BTP0611 tablets in the treatment of patients with chronic heart failure with reduced ejection fraction for 32 weeks, using ivabradine hydrochloride tablets as a control. Secondary objective: To evaluate the safety of BTP0611 tablets in the treatment of patients with chronic heart failure with reduced ejection fraction for 32 weeks, using ivabradine hydrochloride tablets as a control.

Primary objective To evaluate the pharmacokinetic characteristics of BTP0209 tablets (specification: 25 mg) developed by Beijing Sunshine Novo Pharmaceutical Research Co., Ltd. and Nicorandil tablets (Sigma®, specification: 5 mg) developed by Chugai Pharmaceutical Co., Ltd. in Chinese healthy adult subjects after single or multiple oral administration under fasting conditions, and to compare the differences in pharmacokinetic characteristics and relative bioavailability between the two. Secondary objective To evaluate the safety of BTP0209 tablets (specification: 25 mg) and Nicorandil tablets (Sigma®, specification: 5 mg) in Chinese healthy adult subjects after single or multiple oral administration under fasting conditions.

Primary purpose: To evaluate the effectiveness of LXH-2301 on alkalinization of urine in patients with malabsorbed gout and hyperuricemia under the background treatment of 20 mg febuxostat compared with positive drugs and placebo; Secondary purpose: To evaluate the safety and tolerability of LXH-2301 compared with positive drugs and placebo in patients with malabsorbed gout and hyperuricemia under the background treatment of 20 mg febuxostat; Exploratory purpose: To explore the protective effect of LXH-2301 and the combination of positive drugs and febuxostat on renal injury, explore the correlation between LXH-2301 and alkalinization of urine and promotion of urinary uric acid excretion, and the effect of LXH-2301 on serum bicarbonate (HCO3-) and serum uric acid.